Zhailaubay Kydyrbayev

Zhailaubay Kydyrbayev

Auto-generated profile, based on publicly available information

Zhailaubay Kydyrbayev

«Research Institute for Biological Safety Problems» LLP, JSC "National Holding «QazBioPharm

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DBDina Bugybayeva
Dina Bugybayeva
SRSholpan Ryskeldinova
Sholpan Ryskeldinova
NZNadezhda Zinina
Nadezhda Zinina
MSMakhpal Sarmykova
Makhpal Sarmykova
NANurika Narynbekovna Assanzhanova
Nurika Narynbekovna Assanzhanova
KTKaissar Tabynov
Kaissar Tabynov
In this paper, we first used recombinant influenza viral vector (rIVV) subtype H5N1 expressing from the open reading frame of NS1 80 and NS1 124 amino acids of Brucella outer membrane proteins (Omp) 16 and 19, ribosomal L7/L12, and Cu‐Zn superoxide dismutase (SOD) proteins to develop a human brucellosis vaccine. We made 18 combinations of IVVs in mono‐, bi‐, and tetravalent vaccine formulations and tested them on mice to select the safest and most effective vaccine samples. Then, the most effective vaccine candidates were further tested on guinea pigs. Safety of the rIVV‐based vaccine candidate was evaluated by a mouse weight‐gain test. Mice and guinea pigs were challenged with the virulent strain B. melitensis 16M. The protective effect of the rIVV‐based vaccine candidate was assessed by quantitation of Brucella colonization in tissues and organs of challenged animals. All vaccine formulations were safe in mice. Tested vaccine formulations, as well as the commercial B. melitensis Rev.1 vaccine, have been found to protect mice from B. melitensis 16M infection within the range of 1.6 to 2.97 log10 units (P < 0.05). Tetravalent vaccine formulations from the position of NS1 80 amino acids (0.2 ± 0.4), as well as the commercial B. melitensis Rev.1 vaccine (1.2 ± 2.6), have been found to protect guinea pigs from B. melitensis 16M infection at a significant level (P < 0.05). Thus, tetravalent vaccine formulation Flu‐NS1‐80‐Omp16+Flu‐NS1‐80‐L7/L12+Flu‐NS1‐80‐Omp19+Flu‐NS1‐80‐SOD was chosen as a potential vaccine candidate for further development of an effective human vaccine against brucellosis. These results show a promising future for the development of a safe human vaccine against brucellosis based on rIVVs.

27 November 2022 in Biosafety and Biotechnology
Verified
Journal Article
Open access
PDF file
ZKZh. Kydyrbayev
Zh. Kydyrbayev
NAN. N. Asanjanova
N. N. Asanjanova
SRSh. Zh. Ryskeldinova
Sh. Zh. Ryskeldinova
EKE. M. Kozhamkulov
E. M. Kozhamkulov
EKE. K. Kulbekov
E. K. Kulbekov
NAN. Zh. Akmyrzaev
N. Zh. Akmyrzaev
: в работе приведены результаты апробационного испытания физических и биологических свойств опытной серии вакцины против болезни Ньюкасла из штамма Ла-Сота в условиях Национального референтного центра по ветеринарии Комитета ветеринарного контроля и надзора Министерства сельского хозяйства Республики Казахстан (КВКиН МСХ РК) и Научно-исследовательского института проблем биологической безопасности (НИИПББ). Целью исследования являлись апробационные испытания вакцины против болезни Ньюкасла из штамма Ла-Сота. При выполнении работы использованы общие вирусологические, иммунологические методы исследования. Результаты апробационных исследованиии показали, что вакцина без контаминантов, биологическая активность ее составила 9,03 ± 0,14 lg ЭИД50/см3. Вакцина безвредна для цыплят 40 суточного возраста. Вакцина иммуногенна для цыплят. Средние титры антител к вирусу болезни Ньюкасла на 16 сутки после вакцинации составляет 1:127,2 в реакции торможения гемагглютинации (РТГА). Вакцина соответствует по своим физико-биологическим свойствам всем предьявляемым требованиям и пригодна для специфической профилактики болезни Ньюкасла. Апробационные испытания физических, биологических свойств вакцины закончены с положительными результатами и апротоколы, акты исследований подписаны членами Комиссии КВКиН МСХ РК. Рекомендуется широкомасштабное применение вакцины в условиях птицеводческих хозяйств, частных подворий для специфической профилактики болезни Ньюкасла.

15 December 2020 in THE BULLETIN
Verified
Journal Article
Closed access
AMAigerim Mailybayeva
Aigerim Mailybayeva
ANAinur Nurpeisova
Ainur Nurpeisova
NANurika Narynbekovna Assanzhanova
Nurika Narynbekovna Assanzhanova
EKErken Kozhamkulov
Erken Kozhamkulov
IAInkarbekov Dulat A.
Inkarbekov Dulat A.
ZKZakarya K.D.
Zakarya K.D.
This study looks into optimal conditions for cultivating the recombinant strains of subtype H5 influenza virus. The study results in establishing optimal conditions (inoculation dose, incubation temperature, incubation time, and chicken embryos’ age) for growing the influenza virus. This study establishes optimum conditions for cultivating the A/Sichuan/26221/2014(H5N6)-PR8-IDCDC-RG42A and A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A subtype H5 influenza virus recombinant strains in embryonated chicken eggs. Data on culturing influenza virus recombinant strains presented herein indicates that they can be used in developing subtype H5 highly-pathogenic avian influenza vaccines. The results of this research will serve as a basis for developing a new inactivated emulgated vaccine following the process previously used by RIBSP to design its commercial vaccine. These optimum conditions are an infective dose of 10000 EID50/0.2 cm3, an incubation temperature of 36±0.50С, an embryo age of 10 days for cultivating the recombinant strain A/Sichuan/26221/2014(H5N6)-PR8-IDCDC-RG42A. Using these culturing conditions allows a stable production of virus-containing materials with an infectivity level of not less than 8.45±0.24 log EID50/cm3, which is fully consistent with requirements for producing inactivated vaccines for avian influenza. And optimal conditions for growing recombinant strain A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A in 10 days embryonated chicken eggs with the infective dose 100000 EID50 in the incubation temperature 350С. These optimum conditions are helping culturing a stable production of virus-containing materials with an infectivity level of not less than 8.74±0.06 log EID50/cm3, which is fully consistent with requirements for producing inactivated vaccines for recombinant strain A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A. Аn optimum incubation time of 48 hours, and relative air humidity of 55±5% for cultivating both recombinant strains.

31 March 2025 in Biosafety and Biotechnology
Verified
Journal Article
Open access
PDF file
SKS. K. Kopeyev
S. K. Kopeyev
ZKZh. K. Kydyrbayev
Zh. K. Kydyrbayev
RRR. A. Rystayeva
R. A. Rystayeva
KSKamshat Shorayeva
Kamshat Shorayeva
MAMeirim Almezhanova
Meirim Almezhanova
MOMukhit B. Orynbayev
Mukhit B. Orynbayev
Based on the results of an epizootological survey of the area and microbiological studies of pathological material from saigas brought from the West Kazakhstan region during the epizootics of 2010 and 2011, the cause of the mass death of saigas was established. Gram-positive bacteria with spores, located predominantly subterminally, were found in fingerprint smears from the internal organs of a fallen saiga. Bacteriological nutrient media show the growth of bacterial colonies in the form of intense turbidity (MPA), uniform turbidity (Kitt-Tarozzi) with abundant gas formation, colonies of small, round, smooth, colorless (blood agar). Microscopic examination of colonies on Kitt-Tarozzi medium revealed gram-positive, thick, short bacteria. White mice infected with the bacterial culture died after 16-18 hours with signs of plethora and edema. Gram-positive bacteria with rounded ends were found in fingerprint smears from the internal organs of dead mice.Based on the research, it is argued that the saiga died from anaerobic clostridiosis. The species identity of the isolated bacteria (Clostridium histolyticum and Clostridium perfringens) was determined based on the results of studying the biochemical, molecular and genetic properties of the cultures.